Biogen to End Development of Gosuranemab in Progressive Supranuclear Palsy
December 13 2019 - 8:15AM
Dow Jones News
By Colin Kellaher
Biogen Inc. (BIIB) Friday said it is ending development of
gosuranemab for the brain disorder progressive supranuclear palsy
and other primary tauopathies after a phase 2 study missed its
primary endpoint.
The Cambridge, Mass., biopharmaceutical company said the main
endpoint, as measured by the progressive supranuclear palsy rating
scale at week 52, wasn't statistically significant, and said the
study didn't show efficacy on key clinical secondary endpoints.
Biogen, which licensed gosuranemab from Bristol-Myers Squibb Co.
(BMY), said it will continue a Phase 2 study of the drug for mild
cognitive impairment due to Alzheimer's disease or mild AD, given
differences in disease pathology.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 13, 2019 08:00 ET (13:00 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Sep 2023 to Sep 2024